ARWR Stock: Arrowhead Pharmaceuticals Hits New High as FDA Approval and Q4 Earnings Converge
Arrowhead Pharmaceuticals’ stock (NASDAQ: ARWR) is entering Tuesday, November 25, 2025 on a hot streak, buoyed by its first FDA‑approved drug, fresh milestone payments, and a big‑ticket partnership with Novartis. Together, these catalysts have turned ARWR into one of the